Xiamen Amoytop Biotech Co Ltd
医疗健康 · 生物科技
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.
MARKET 市值 22.74B CNY PE 22.6x
52W ¥50 – ¥93.52
EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG — 营收 YoY 18.5%
▲ ROE 31.8% 营业利润率 24.6% 净利润率 26.5%
ANALYST 股息率 1.13%